Moderna Inc
NASDAQ: MRNA
$41.11
+$2.86 (+7.5%)
Closing Price on November 22, 2024
MRNA Articles
When Moderna reported its most recent quarterly results before the markets opened on Thursday, the earnings (or loss in this case) were not the most important feature of the report.
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others. Before getting into an actual prediction basis for knowing which vaccine (or...
Published:
Tuesday's top analyst upgrades and downgrades include Apple, Baidu, Boeing, Delta Air Lines, L3Harris Technologies, Moderna, Raytheon Technologies, Roku and Walt Disney.
Published:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
Independent research firm Argus has reiterated its Buy rating on Moderna and is calling this large pullback a buying opportunity.
Published:
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Published: